Analysts See $-0.67 EPS for Stemline Therapeutics, Inc. (STML)

February 24, 2018 - By Winifred Garcia

 Analysts See $ 0.67 EPS for Stemline Therapeutics, Inc. (STML)
Investors sentiment increased to 1.24 in Q3 2017. Its up 0.24, from 1 in 2017Q2. It is positive, as 6 investors sold Stemline Therapeutics, Inc. shares while 19 reduced holdings. 13 funds opened positions while 18 raised stakes. 12.54 million shares or 4.36% more from 12.02 million shares in 2017Q2 were reported.
Sei Co stated it has 130 shares or 0% of all its holdings. Credit Suisse Ag holds 16,756 shares or 0% of its portfolio. Fmr Lc invested in 2.00M shares. Tower Ltd Liability Corp (Trc) reported 0% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML). Tiaa Cref Investment Mgmt Ltd holds 0% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML) for 53,900 shares. Bailard Incorporated invested in 64,600 shares. Sphera Funds Limited, Israel-based fund reported 300,000 shares. Nationwide Fund Advsr has invested 0% in Stemline Therapeutics, Inc. (NASDAQ:STML). Alliancebernstein Lp holds 19,300 shares or 0% of its portfolio. Sabby Mngmt Llc has 0.03% invested in Stemline Therapeutics, Inc. (NASDAQ:STML). Carl Domino invested 0.35% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML). New York State Common Retirement Fund invested 0% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML). Adage Cap Partners Grp Limited Liability Company has 0.02% invested in Stemline Therapeutics, Inc. (NASDAQ:STML) for 657,358 shares. Blackrock holds 0% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML) for 1.32M shares. Balyasny Asset Ltd Liability holds 0% or 17,400 shares.

Since December 15, 2017, it had 0 buys, and 5 sales for $511,958 activity. 3,820 shares were sold by Bergstein Ivan, worth $60,356 on Thursday, February 15. Gionco David also sold $57,078 worth of Stemline Therapeutics, Inc. (NASDAQ:STML) on Wednesday, January 17.

Analysts expect Stemline Therapeutics, Inc. (NASDAQ:STML) to report $-0.67 EPS on March, 15.They anticipate $0.11 EPS change or 19.64 % from last quarter’s $-0.56 EPS. After having $-0.68 EPS previously, Stemline Therapeutics, Inc.’s analysts see -1.47 % EPS growth. The stock increased 0.85% or $0.15 during the last trading session, reaching $17.75. About 309,443 shares traded or 9.59% up from the average. Stemline Therapeutics, Inc. (NASDAQ:STML) has risen 52.65% since February 24, 2017 and is uptrending. It has outperformed by 35.95% the S&P500.

Stemline Therapeutics, Inc. (NASDAQ:STML) Ratings Coverage

Among 4 analysts covering Stemline Therapeutics Inc (NASDAQ:STML), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Stemline Therapeutics Inc had 13 analyst reports since November 10, 2015 according to SRatingsIntel. On Friday, February 2 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was maintained by Cowen & Co with “Buy” on Friday, June 23. H.C. Wainwright maintained the shares of STML in report on Friday, November 10 with “Buy” rating. H.C. Wainwright maintained Stemline Therapeutics, Inc. (NASDAQ:STML) on Wednesday, November 1 with “Buy” rating. On Monday, February 6 the stock rating was maintained by Wedbush with “Outperform”. The stock of Stemline Therapeutics, Inc. (NASDAQ:STML) has “Buy” rating given on Thursday, December 14 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, September 12. The firm has “Buy” rating given on Wednesday, August 9 by H.C. Wainwright. H.C. Wainwright maintained the stock with “Buy” rating in Monday, June 26 report. Cowen & Co maintained Stemline Therapeutics, Inc. (NASDAQ:STML) on Wednesday, June 14 with “Buy” rating.

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The company has market cap of $514.25 million. The firm develops SL-401, a targeted therapy directed to the interleukin-3 receptor , which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It currently has negative earnings. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer.

More important recent Stemline Therapeutics, Inc. (NASDAQ:STML) news were published by: Globenewswire.com which released: “Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock” on January 26, 2018, also Fool.com published article titled: “The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33%”, Globenewswire.com published: “Stemline Therapeutics Announces Proposed Public Offering of Common Stock” on January 22, 2018. More interesting news about Stemline Therapeutics, Inc. (NASDAQ:STML) was released by: Fool.com and their article: “Here’s Why Stemline Therapeutics Inc. Jumped 23% Higher in October” with publication date: November 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: